Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Geologica Closes Financing And Property Acquisition (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

InMed Pharmaceuticals Inc INM

Healthcare Cannabis
InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing a pipeline of prescription-based products, including rare cannabinoids and cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs, as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its segments include InMed Pharmaceuticals and BayMedica. The InMed Pharmaceuticals segment is engaged in research and development of cannabinoid-based pharmaceutical products. The BayMedica segment is focused on developing manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 is used for the treatment of glaucoma.


NDAQ:INM - Post by User

InMed Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(12)
•••
Post by stockman691on Jan 23, 2017 11:38am
249 Views
Post# 25741511

Form 9 from latest PP at .18

Form 9 from latest PP at .18
$IMLFF According to the recently released Form 9 from last PP at .18
InMed Private Placement names are in the public domain: Dundee is one of the largest Investment banks in Marijuana in Canada 
Peter Brown
 
Founder, Canaccord Genuity 
 
 
Dundee Capital Markets
Donato
Sferra
Managing Director , Investment Banking
Mark
Attasnasio
President
Jamieson
Bondarenko
‎Managing Director
Stuart
Smith
 SVP, Institutional Equity Trading 
Bruce
Latimer
Senior Equity Trader
Rayna
Schnapp
Institutional Equity Sales
Pat
McBride
Director Institutional Equity Sales
David
Morrison
Head of Equities
Richard
Livesely
Investment Banking Analyst 
Chad
Macdonald
‎Partner, Institutional Equity Trader
Winston
Myles
Institutional Equity Sales
Tanner
Kohera
Director, Institutional Sales
Michelle
Goh
Partner

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities